Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 9Endometrial Neoplasms 4Carcinoma, Renal Cell 4Neuroendocrine Tumors 3Tuberous Sclerosis 2Recurrence 2Neoplasm Metastasis 2Kidney Neoplasms 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Solid Tumor 1Seizures 1Sarcoma 1Primary Non-metastatic Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Hyperplasia 1Clear-cell metastatic renal cell carcinoma 1Breast Neoplasms, Male 1Angiomyolipoma 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

selpercatinib 2binimetinib 1Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Diseases × Everolimus × Clear all
NCT01141309 2025-07-22

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
41 enrolled
Head & Neck

Thyroid Diseases, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡